Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) achieves Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application
- The cough counter tracks cough frequency using ResApp’s machine learning algorithms that accurately identify coughs from a smartphone’s microphone
- This technology is already being used by AstraZeneca to monitor patients participating in a lung cancer clinical trial and an asthma management support program
- Additionally, it is now listed on the Australian Register of Therapeutic Goods and is available for sale in Europe as a class I medical device
- Shares in ResApp are steady on the market and are trading at 5.6 cents
ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.
The cough counter tracks cough frequency using ResApp’s machine learning algorithms that accurately identify coughs from a smartphone’s microphone.
Additionally, it is now listed on the Australian Register of Therapeutic Goods and is available for sale in Europe as a class I medical device.
ResApp’s cough counting technology is already being used by AstraZeneca to monitor patients participating in a lung cancer clinical trial and an asthma management support program.
CEO and Managing Director Dr Tony Keating is pleased to have secured regulatory clearance.
“We are pleased to have secured regulatory clearance in Australia and Europe for our cough counting technology,” Dr Keating commented.
“The ability to measure cough frequency using only a smartphone is a highly scalable solution that has a number of broad clinical applications.
“After our success in partnering with AstraZeneca, we are particularly excited about the opportunity in supporting clinical trials, where cough can provide important insight into the progressing of disease and efficacy of treatment.”
ResApp was steady on the market, with shares trading at 5.6 cents at 11:24 am AEDT.
